Bromdiphenylessigsaeure-methylester | 104488-36-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Bromdiphenylessigsaeure-methylester
• 英文别名: methyl 2-bromo-2,2-diphenylacetate；bromo-diphenyl-acetic acid methyl ester；Methyl bromo(diphenyl)acetate
• CAS: 104488-36-0
• 化学式: C₁₅H₁₃BrO₂
• 分子量: 305.171
• InChiKey: GMOPDUWWJUWBKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Bromdiphenylessigsaeure-methylester 在 铜 作用下， 以 四氯化碳 为溶剂， 反应 2.0h， 以82%的产率得到<4-<(Methoxycarbonyl)phenylmethylen>-2,5-cyclohexadien-1-yl>diphenylessigsaeure-methylester
  参考文献：
  名称：

  Neumann, Wilhelm P.; Stapel, Ralf, Chemische Berichte, 1986, vol. 119, # 11, p. 3422 - 3431

  摘要：

  DOI：
• 作为产物：
  描述：

  二苯乙醇酸甲酯 在 溴 、 三溴化磷 作用下， 生成 Bromdiphenylessigsaeure-methylester
  参考文献：
  名称：

  Carothers, Journal of the American Chemical Society, 1926, vol. 48, p. 3195

  摘要：

  DOI：

文献信息

• [EN] MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES<br/>[FR] PIPERIDINES D'ARYLE OU PIPERAZINES SUBSTITUEES PAR DES HETEROCYCLES A 5 RAMIFICATIONS INHIBANT LA MTP
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005085226A1

  公开（公告）日：2005-09-15

  The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes (Formula (I)). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hyper­triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.

  本发明涉及新颖的芳基哌啶或哌嗪化合物，其被某些含有apoB分泌/MTP抑制活性和伴随的降脂活性的5-成员杂环取代。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗高脂血症、肥胖症和2型糖尿病的药物的用途（公式（I））。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗动脉粥样硬化、胰腺炎、肥胖症、高甘油三酯血症、高胆固醇血症、高脂血症、糖尿病和2型糖尿病的药物的用途。
• Synthesis of 3,3-Disubstituted-2-Piperazinones
  作者：Tetsuji Kametani、William Taub、David Ginsburg

  DOI：10.1246/bcsj.31.860

  日期：1958.7

  Several 3,3-disubstituted-2-piperazinones have been synthesized for pharmacological testing as potential hypnotics.

  已经合成了几种 3,3-二取代-2-哌嗪酮，作为潜在的催眠药进行药理测试。
• PRODUCTION METHOD FOR POLYMER, COMPOUND CONTAINING RADICAL-POLYMERIZATION INITIATION GROUP, AND POLYMER
  申请人：Dainichiseika Color & Chemicals Mfg. Co., Ltd.

  公开号：EP3604354A1

  公开（公告）日：2020-02-05

  Provided are: a novel polymerization technique by which a polymer having a controlled molecular weight or molecular weight distribution or a polymer having a desirably regulated, complicated structure can be obtained using commercially available general-purpose materials without using any radical polymerization initiator, or any special material for use in living radical polymerization and without requiring any strict polymerization conditions; a radical polymerization initiation group-containing compound for use in the technique; and a polymer obtained thereby. Specifically, provided are: a method for producing a polymer, the method including a polymerization step of mixing and warming (1) a radically polymerizable monomer, (2) an organic compound having at least one group introduced in a molecule thereof, the group functioning as a polymerization initiation group for the monomer and having a structure represented by formula 1, and (3) a chloride ion-containing and/or bromide ion-containing compound selected from among specific compounds, thereby initiating radical polymerization from the group having the structure, the radical polymerization accompanying a termination reaction; a radical polymerization initiation group-containing compound; and a polymer.

  提供了：一种新型聚合技术，通过该技术可以使用市售通用材料获得具有可控分子量或分子量分布的聚合物或具有理想调节的复杂结构的聚合物，而无需使用任何自由基聚合引发剂或用于活自由基聚合的任何特殊材料，也不需要任何严格的聚合条件；一种用于该技术的含自由基聚合引发基团的化合物；以及由此获得的聚合物。具体地说，提供了一种生产聚合物的方法，该方法包括以下聚合步骤：(1)可自由基聚合的单体；(2)在其分子中引入至少一个基团的有机化合物，该基团作为单体的聚合引发基并具有式 1 所表示的结构；(3)从特定化合物中选出的含氯离子和/或含溴离子的化合物，从而从具有该结构的基团引发自由基聚合，自由基聚合伴随着终止反应；含自由基聚合引发基团的化合物；以及聚合物。
• Carothers, Journal of the American Chemical Society, 1926, vol. 48, p. 3195
  作者：Carothers

  DOI：——

  日期：——
• Structure–activity relationships in platelet-activating factor. Part 13: Synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity
  作者：Nawal Serradji、Okkacha Bensaid、Marc Martin、Wafa Sallem、Nathalie Dereuddre-Bosquet、Houcine Benmehdi、Catherine Redeuilh、Aazdine Lamouri、Georges Dive、Pascal Clayette、Françoise Heymans

  DOI：10.1016/j.bmc.2006.07.031

  日期：2006.12

  HIV-1 infection of the brain and PAF neurotoxicity are implicated in AIDS dementia complex. We previously reported that a trisubstituted piperazine derivative is able to diminish both HIV-1 replication in monocyte-derived macrophages and PAF-induced platelet aggregation. We report in this work new compounds obtained by modifying its piperazine substituents. The structure-activity relationship study shows that a better dual activity or even pure antiretroviral compounds can be obtained in this series. (c) 2006 Elsevier Ltd. All rights reserved.